Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib plus immune checkpoint inhibitor rechallenge after resolved irAEs in solid tumors
ChiCTR2600134216Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tofacitinib in Nonhematologic neoplasms, sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Discontinuation rate due to irAE recurrence within 3 months and Disease Control Rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2600134216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134216.